Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 1, 2011, Pages 32-37

  Worodria, William ^a,b,c   Massinga Loembe, Marguerite ^d   Mazakpwe, Doreen ^c   Luzinda, Kenneth ^c   Menten, Joris ^d   Van Leth, Frank ^e,f   Mayanja Kizza, Harriet ^a,c   Kestens, Luc ^b,d   Mugerwa, Roy D ^a,c   Reiss, Peter ^e   Colebunders, Robert ^b,c,d  

^a MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Infectious Diseases Network for Treatment and Research in Africa   (Uganda)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

Author keywords

HIV; Immune reconstitution; Mortality; Predictors; Tuberculosis

Indexed keywords

ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CRYPTOCOCCOSIS; DEATH; FEMALE; HAZARD RATIO; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SCREENING; TUBERCULIN TEST; TUBERCULOSIS; MIDDLE AGED; RISK FACTOR; UGANDA;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; TUBERCULOSIS; UGANDA;

EID: 80054073495     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182255dc2     Document Type: Article

References (40)

1. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009-1021. (Pubitemid 36548927)
2. Harries AD, Nyirenda T, Banerjee A, et al. Tuberculosis control in the face of the HIV epidemic. Trop Doct. 1998;28:243-245. (Pubitemid 28475156)
3. Zwang J, Garenne M, Kahn K, et al. Trends in mortality from pulmonary tuberculosis and HIV/AIDS co-infection in rural South Africa (Agincourt). Trans R Soc Trop Med Hyg. 2007;101:893-898. (Pubitemid 47091461)
4. Whalen C, Horsburgh CR, Hom D, et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med. 1995;151:129-135.
5. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897-1908.
6. Pepper DJ, Marais S, Wilkinson RJ, et al. Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors. BMC Infect Dis. 2010;10:83.
7. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS. 2007;21:713-719. (Pubitemid 46568628)
8. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697-706.
9. Boulle A, Clayden P, Cohen K, et al. Prolonged deferral of antiretroviral therapy in the SAPIT trial: Did we need a clinical trial to tell us that this would increase mortality? S Afr Med J. 2010;100:566.
10. Blanc FX, Sok T, Laureillard D, et al. Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. Presented at: XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria: Journal of The International AIDS Society.
11. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2006 revision.
12. Komati S, Shaw PA, Stubbs N, et al. Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa. AIDS. 2010;24:1849-1855.
13. Manosuthi W, Chottanapand S, Thongyen S, et al. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;43:42-46. (Pubitemid 44306486)
14. MOH. National Antiretroviral Treatment Guidelines for Adults, Adolescents, and Children. Kampala, Uganda: Ministry of Health; July 2008.
15. WHO. Improving the Diagnosis and Treatment of Smear-Negative Pulmonary and Extrapulmonary Tuberculosis Among Adults and Adolescents. Recommendations for HIV-Prevalent and Resource-Constrained Settings. Geneva, Switzerland: World Health Organization; 2007. WHO/HTM/TB/2007.379, WHO/HIV/2007.01.
16. MOH. Manual of the National Tuberculosis and Leprosy Programme. Kampala, Uganda: Ministry of Health; 2010.
17. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516-523. (Pubitemid 352005824)
18. Hanrahan CF, Golub JE, Mohapi L, et al. Body mass index and risk of tuberculosis and death. AIDS. 2010;24:1501-1508.
19. van der Sande MA, Schim van der Loeff MF, Aveika AA, et al. Body mass index at time of HIV diagnosis: a strong and independent predictor of survival. J Acquir Immune Defic Syndr. 2004;37:1288-1294. (Pubitemid 39281511)
20. Kingkaew N, Sangtong B, Amnuaiphon W, et al. HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death. Int J Infect Dis. 2009;13:722-729.
21. Richter C, Koelemay MJ, Swai AB, et al. Predictive markers of survival in HIV-seropositive and HIV-seronegative Tanzanian patients with extrapulmonary tuberculosis. Tuber Lung Dis. 1995;76:510-517. (Pubitemid 26008706)
22. Cain KP, Anekthananon T, Burapat C, et al. Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerg Infect Dis. 2009;15:258-264.
23. Akksilp S, Karnkawinpong O, Wattanaamornkiat W, et al. Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis. 2007;13:1001-1007. (Pubitemid 47048071)
24. Tabarsi P, Saber-Tehrani AS, Baghaei P, et al. Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. J Int AIDS Soc. 2009;12:14.
25. WHO. Rapid Advice for Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva, Switzerland: World Health Organization; November 2009.
26. Sendagire I, Schreuder I, Mubiru M, et al. Low HIV testing rates among tuberculosis patients in Kampala, Uganda. BMC Public Health. 2010;10:177.
27. Wanyenze RK, Nawavvu C, Namale AS, et al. Acceptability of routine HIV counselling and testing, and HIV seroprevalence in Ugandan hospitals. Bull World Health Organ. 2008;86:302-309. (Pubitemid 351521857)
28. Nakanjako D, Kamya M, Daniel K, et al. Acceptance of routine testing for HIV among adult patients at the medical emergency unit at a national referral hospital in Kampala, Uganda. AIDS Behav. 2007;11:753-758. (Pubitemid 47327564)
29. Cornell M, Myer L, Kaplan R, et al. The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health. 2009;14:722-731.
30. Murdoch DM, Venter WD, Feldman C, et al. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS. 2008;22:601-610. (Pubitemid 351640593)
31. Tansuphasawadikul S, Saito W, Kim J, et al. Outcomes in HIV-infected patients on antiretroviral therapy with tuberculosis. Southeast Asian J Trop Med Public Health. 2007;38:1053-1060.
32. Lawn SD, Myer L, Bekker LG, et al. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS. 2007;21:335-341. (Pubitemid 46175045)
33. Muller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:251-261.
34. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health. 2007;12:929-935. (Pubitemid 47245826)
35. Meya DB, Manabe YC, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51:448-455.
36. Zachariah R, Harries K, Moses M, et al. Very early mortality in patients starting antiretroviral treatment at primary health centres in rural Malawi. Trop Med Int Health. 2009;14:713-721.
37. Johannessen A, Naman E, Ngowi BJ, et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008;8:52.
38. Jones-Lopez EC, Okwera A, Mayanja-Kizza H, et al. Delayed-type hypersensitivity skin test reactivity and survival in HIV-infected patients in Uganda: should anergy be a criterion to start antiretroviral therapy in low-income countries? Am J Trop Med Hyg. 2006;74:154-161. (Pubitemid 46768645)
39. Gustafson P, Gomes VF, Vieira CS, et al. Clinical predictors for death in HIV-positive and HIV-negative tuberculosis patients in Guinea-Bissau. Infection. 2007;35:69-80. (Pubitemid 46536772)
40. Serrat C, Gomez G, Garcia de Olalla P, et al. CD4+ lymphocytes and tuberculin skin test as survival predictors in pulmonary tuberculosis HIV-infected patients. Int J Epidemiol. 1998;27:703-712. (Pubitemid 28431517)